Summary: Biotalys has announced a strategic refocus to concentrate resources on its most advanced protein-based biocontrol programs, including EVOCA NG and BioFun-6. This restructuring aims to reduce total cash burn by €20 million through 2028, streamlining operations and right-sizing the organization to accelerate the path to commercialization and long-term value creation.
Biotalys Proceeds with Strategic Refocus to Prioritize Core Assets and Extend Runway
Ghent, BELGIUM — February 09, 2026
Biotalys (Euronext: BTLS), an AgTech company developing protein-based biocontrols for sustainable crop protection, today announced its intention to proceed with a strategic refocus designed to concentrate resources on its highest-priority programs and streamline operations accordingly.
As part of this initiative, Biotalys intends to right-size its organizational structure and suspend early-stage activities to reduce operating expenses. This move is expected to result in an estimated reduction in total cash burn of €20 million until the end of 2028 compared to the current operating structure. The company confirms its cash runway remains into May 2026.
- Lead Biofungicides: Resources will focus on progressing EVOCA NG and BioFun-6 toward commercialization.
- Active Partnerships: Continued support for BioFun-7 (Gates Foundation) and BioIns-2 (insecticide program with Syngenta).
- Commercial Timeline: EVOCA NG is planned for a US launch in 2029 and Europe in 2030, targeting a $1.1 billion combined market.
- Manufacturing Efficiency: Ongoing process development with 21st.BIO to achieve commercially competitive manufacturing costs.
“It is imperative that we deploy capital where it creates the greatest impact,” said Kevin Helash, CEO of Biotalys. “A narrowing of the focus to our core assets and most advanced programs aims to strengthen our ability to deliver innovative, sustainable crop protection solutions to growers and advance our path to long-term value creation.”
In alignment with this sharpened strategy, Biotalys announced the intention to reduce its workforce by 30 employees. The company is currently in discussions with investors regarding potential financing options to support the refocused portfolio and its goal of becoming a pioneer of Precision Biocontrols.
About EVOCA™
EVOCA helps control Botrytis (grey mold) and powdery mildew in fruits and vegetables. Following the EPA approval of the first-generation version in late 2025, Biotalys anticipates a significantly shorter regulatory review process for EVOCA NG as it shares the same active ingredient.
About Biotalys
Based in Ghent, Belgium, Biotalys develops precision protein-based biocontrol solutions via its novel AGROBODY™ technology platform, bridging the efficacy of chemistry with the environmental benefits of biologicals.
Leave a Reply